EUVIMEDEUVIMED entdecken
Crossref

2026 American Association for Thoracic Surgery (AATS) expert consensus statement: Antithrombotic management of neonates/infants undergoing cardiac interventions

Meena Nathan, Amy L Kiskaddon, Sirisha Emani, Amee M Bigelow, Ryan M Callahan, John D Cleveland, Myke Federman, Michael Ma, D Michael McMullan, Arshid Mir, Joshua Branstetter, Christina VanderPluym und 1 weitere

The Journal of Thoracic and Cardiovascular Surgery · 2026-09 · 172 (3) · 618-662.e7

DOI: 10.1016/j.jtcvs.2026.03.617 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2026-09. Verfasst von Meena Nathan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Mass. Electronic address: meena.nathan@cardio.chboston.org. Hauptthemen laut MEDLINE: Cardiac Surgical Procedures, Fibrinolytic Agents, Heart Defects, Congenital. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 152 Literaturangaben. Gefördert von: School of Medicine, Johns Hopkins University, Harvard Medical School.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The hemostatic system in neonates and infants with congenital heart disease is distinct as a result of developmental and disease-specific factors, necessitating population-specific periprocedural evaluation and antithrombotic management. Ongoing practice variation reflects limited evidence and highlights the need for structured guidance and further study. METHODS: To develop a more unified management strategy for periprocedural antithrombotic testing and therapy in this vulnerable population, a group of experts (cardiac surgeons, cardiologists, interventionalist, hematologists, intensivists, and pharmacologists) commissioned by the American Association for Thoracic Surgery was convened to define the basic differences in the hemostatic systems of neonates and infants compared with older children and adults and develop a framework for periprocedural antithrombotic management in neonates and infants undergoing congenital cardiac interventions using the modified Delphi methodology. RESULTS: Consensus was reached on all 34 statements and related figures and tables. These provide information specific to neonates and infants with congenital heart disease on the coagulation cascade; testing for congenital, acquired, and therapy-related abnormalities in the hemostatic system; and commonly used antithrombotic (anticoagulant and antiplatelet) agents and their monitoring. Recommendations were made on pre-, intra-, and postprocedural antithrombotic management, including procedure and device-specific recommendations both in the short and long term. CONCLUSIONS: The hemostatic system in neonates and infants with congenital heart disease is distinct from that of older children and adults and warrants focused periprocedural evaluation and therapy. These recommendations guide understanding of the complex interactions during antithrombotic management in this patient population during cardiac surgical and catheter-based interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiac Surgical ProceduresFibrinolytic AgentsHeart Defects, CongenitalHumansInfantInfant, NewbornDelphi TechniqueRisk FactorsUnited States

Stichwörter der Autor:innen

antithrombotic therapycoagulation cascadecongenital cardiac interventionsneonates and infantsperturbations of the coagulation system

Substanzen

Fibrinolytic Agents

Autor:innen und Institutionen

  • Department of Cardiac Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Mass. Electronic address: meena.nathan@cardio.chboston.org.
  • Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Md.
  • Department of Cardiac Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Mass.
  • Department of Pediatrics, Nationwide Children's Hospital, Ohio State University, Columbus, Ohio.
  • Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pa.
  • Division of Cardiothoracic Surgery, Children's Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, Calif.

Förderung

  • School of Medicine, Johns Hopkins University
  • Harvard Medical School

Zitieren

APA

Nathan, M., Kiskaddon, A. L., Emani, S., Bigelow, A. M., Callahan, R. M., Cleveland, J. D., Federman, M., Ma, M., McMullan, D. M., Mir, A., Branstetter, J., VanderPluym, C., & Yerebakan, C. (2026). 2026 American Association for Thoracic Surgery (AATS) expert consensus statement: Antithrombotic management of neonates/infants undergoing cardiac interventions. The Journal of Thoracic and Cardiovascular Surgery, 172(3), 618-662.e7. https://doi.org/10.1016/j.jtcvs.2026.03.617

Vancouver

Nathan M, Kiskaddon AL, Emani S, Bigelow AM, Callahan RM, Cleveland JD, et al. 2026 American Association for Thoracic Surgery (AATS) expert consensus statement: Antithrombotic management of neonates/infants undergoing cardiac interventions. The Journal of Thoracic and Cardiovascular Surgery. 2026;172(3):618-662.e7. doi:10.1016/j.jtcvs.2026.03.617

BibTeX
@article{Nathan2026,
  author = {Nathan, Meena and Kiskaddon, Amy L and Emani, Sirisha and Bigelow, Amee M and Callahan, Ryan M and Cleveland, John D and Federman, Myke and Ma, Michael and McMullan, D Michael and Mir, Arshid and Branstetter, Joshua and VanderPluym, Christina and Yerebakan, Can},
  title = {2026 American Association for Thoracic Surgery (AATS) expert consensus statement: Antithrombotic management of neonates/infants undergoing cardiac interventions},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2026},
  volume = {172},
  number = {3},
  pages = {618--662.e7},
  doi = {10.1016/j.jtcvs.2026.03.617}
}
Kostenlos starten →